Johnson & JohnsonvsPhathom Pharmaceuticals

JNJ and PHAT stock compared: price, dividend, valuation and results, from SEC filings.

PHAT

Phathom Pharmaceuticals, Inc.

$5.12

Value $403M

-12.93%
PHAT's page

Johnson & Johnson (JNJ) has a market value of $665B and Phathom Pharmaceuticals (PHAT) $403M. Over the last year, with dividends, JNJ moved +41.5% and PHAT -64.5%. Dividend yield: JNJ 1.91%, PHAT none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$665B

    PHAT$403M

    JNJ is 1,649 times PHAT

  • Revenue, 12 months

    JNJ$99.3B

    PHAT$275M

    JNJ is 361 times PHAT

  • Net income, 12 months

    JNJ$16.1B

    PHAT-$83M

  • Operating margin

    JNJ–

    PHAT-9.3%

  • ROIC

    JNJ12.4%

    PHAT–

  • P/E

    JNJ41.3

    PHAT–

  • Dividend yield

    JNJ1.9%

    PHAT0.0%

    1.9 points apart

  • 5-year return

    JNJ+94.4%

    PHAT-75.7%

    170.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+94.4%

PHAT-75.7%

010020020222023202420252026
Returns by period
PeriodJNJWith dividendsPHATWith dividends
1 year since November 17, 2025+41.5%Price +38.4%-64.5%Price -64.5%
3 years since November 17, 2023+100.8%+26.2% a yearPrice +84.4%-31.7%-11.9% a yearPrice -31.7%
5 years since November 17, 2021+94.4%+14.2% a yearPrice +69.1%-75.7%-24.6% a yearPrice -75.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonPHATPhathom Pharmaceuticals

Valuation

JNJPHAT
Valuation
Price$276.11$5.12
Market value$665B$403M
Enterprise value (EV)$693B–
P/E41.3–
P/E, 5-year median21.9–
P/B8.2–
EV/EBIT39.1–
Free cash flow yield3.1%–

Results and growth

JNJPHAT
Results and growth
Revenue, 12 months$99.3B$275M
Net income, 12 months$16.1B-$83M
Free cash flow, 12 months$20.6B-$21M
Earnings per share, 12 months$6.59-$1.01
Revenue growth, year on year6.1%216.9%
Revenue growth a year, past+2.7%over 5 years–
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJPHAT
Margins and returns on capital
Gross margin67.6%80.7%
Operating margin–-9.3%
Net margin16.2%-30.2%
ROIC12.4%–
ROE19.7%–

Balance sheet

JNJPHAT
Balance sheet
Cash$17.2B$185M
Total debt$44.7B–
Net debt / EBITDA1.1–
Interest cover18.0×-0.4×

Dividends and buybacks

JNJPHAT
Dividends and buybacks
Dividend yield1.9%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or PHAT

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Phathom Pharmaceuticals?

By market value, Johnson & Johnson ($665B) is about 1,649.3 times Phathom Pharmaceuticals ($403M), at today's prices.

How did JNJ and PHAT stock do over the last 5 years?

Since November 17, 2021, JNJ's price moved +69.1% and PHAT's -75.7%. With dividends: JNJ +94.4% (+14.2% a year), PHAT -75.7% (-24.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or PHAT?

The dividend yield at today's price is 1.91% for Johnson & Johnson and none for Phathom Pharmaceuticals. Over the last twelve months they paid $5.28 and – per share.

Which has the higher profit margins, Johnson & Johnson or Phathom Pharmaceuticals?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and -30.2% for Phathom Pharmaceuticals, and the operating margin – and -9.3%. Revenue was $99.3B and $275M.

Which is the better investment, Johnson & Johnson or Phathom Pharmaceuticals?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.